重磅！NSCLC药物发展简史( 十 )

【参考文献】
1、Cancer incidence and mortality in China, 2015. Journalof the National Cancer Center. February 10, 2021;21:22
2、Krista L. Noonan et al, The Influence of theEvolution of First-Line Chemotherapy on Steadily Improving Survival in AdvancedNon–Small-Cell Lung Cancer ClinicalTrials, J Thorac Oncol.2015;10:1523-1531
3、Clinical Relevance of KRAS in Human Cancers.Journal of Biomedicine and Biotechnology. 2010; 6:1-13
4、Lieping Chen. Anti–PD-1/PD-L1 therapy of humancancer: past, present, and future.J Clin Invest. 2015;125(9):3384–3391.
6、Difan Zheng et al. MET exon 14 skipping defines a unique molecular class ofnon-small cell lung cancer. Oncotarget.2016 Jul5; 7(27):41691-41702
7、NCCN Clinical Practice Guidelines in Oncology NSCLC Version 3, Feb 16, 2021
8、中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南（2020年）
9、Wang et al., Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligandof LAG-3, Cell (2019), https://doi.org/10.1016/j.cell.2018.11.010
10、Charlene M et al. Mechanisms of Resistance to Immune Checkpoint Blockade:Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients？2019 ASCO EDUCATIONAL BOOK.147-164
11、田季平等，免疫检查点PD-1/PD-L1小分子抑制剂的研究进展，中国药科大学学报 2019,50（1）：1-10
【声明】
本文观点仅代表作者本人，不代表美柏医健立场，欢迎交流补充
▲点击小程序，查看500+海外创新项目